Integrated analyses of phase I and II trials (ALKA-372-001, STARTRK-1, and STARTRK-2) were conducted for entrectinib monotherapy in ROS1 fusion mutation-positive NSCLC. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.